George Martin Biography and Net Worth



George Kelly Martin currently serves as Chairman of Transition Bio, Inc., a molecular condensates discovery company, a role which he has held since 2020, and as Vice Chairman of Ride Therapeutics, Inc., a molecular logistics company, a role which he has held since 2022. He has also served as Chairman of WaveBreak (formerly Wren Therapeutics, Inc.), a company that utilizes physical science and kinetics to create therapeutic solutions for protein misfolding diseases, since 2018.

Previously, George served as President and Chief Executive Officer of Radius Health, Inc., a bone and women’s health company, from 2020 to 2022. Prior to that, George served as Chief Executive Officer of Novan, Inc., a development-stage dermatology company, from 2018 to 2020. Prior to joining Novan, Inc., George was the Chief Executive Officer of Malin Corporation PLC, a life sciences investment company, from 2015 to 2017. George also served as Chief Executive Officer of Elan Corporation plc, an Ireland-based neurodegeneration research and development company, from 2003 to 2013. George’s business career started in finance and capital markets, having spent 21 years at Merrill Lynch & Co. Inc. At the time of his departure from Merrill Lynch in 2002, he was a member of the company’s Executive Operating Committee and his tenure included leadership oversight of four global divisions (debt markets, international equities, Information Technology, and International Private Banking). While at Merrill Lynch, George served multi-year assignments in both Tokyo and London. He previously served on the boards of directors of Questcor Pharmaceuticals, Immunocore Holdings, plc, and Kymab Ltd.

George received his B.A. in Politics from Princeton University.

What is George Kelly Martin's net worth?

The estimated net worth of George Kelly Martin is at least $1.00 million as of August 28th, 2024. Mr. Martin owns 247,176 shares of TriSalus Life Sciences stock worth more than $1,002,299 as of June 22nd. This net worth estimate does not reflect any other assets that Mr. Martin may own. Learn More about George Kelly Martin's net worth.

How do I contact George Kelly Martin?

The corporate mailing address for Mr. Martin and other TriSalus Life Sciences executives is 6272 West 91st Avenue, Westminster, CO 80031, United States. TriSalus Life Sciences can also be reached via phone at 888-321-5212 and via email at [email protected]. Learn More on George Kelly Martin's contact information.

Has George Kelly Martin been buying or selling shares of TriSalus Life Sciences?

George Kelly Martin has not been actively trading shares of TriSalus Life Sciences within the last three months. Most recently, George Kelly Martin sold 9 shares of the business's stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $5.50, for a transaction totalling $49.50. Following the completion of the sale, the director now directly owns 247,176 shares of the company's stock, valued at $1,359,468. Learn More on George Kelly Martin's trading history.

Who are TriSalus Life Sciences' active insiders?

TriSalus Life Sciences' insider roster includes Bryan Cox (Chief of Research), Gary Gordon (Director), and George Martin (Director). Learn More on TriSalus Life Sciences' active insiders.

Are insiders buying or selling shares of TriSalus Life Sciences?

During the last twelve months, TriSalus Life Sciences insiders bought shares 5 times. They purchased a total of 719,682 shares worth more than $1,804,176.38. During the last twelve months, insiders at the sold shares 11 times. They sold a total of 30,150 shares worth more than $119,849.35. The most recent insider tranaction occured on May, 15th when Director Mats Wahlstrom bought 60,000 shares worth more than $151,800.00. Insiders at TriSalus Life Sciences own 16.3% of the company. Learn More about insider trades at TriSalus Life Sciences.

Information on this page was last updated on 5/15/2026.

George Kelly Martin Insider Trading History at TriSalus Life Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/28/2024Sell9$5.50$49.50247,176View SEC Filing Icon  
See Full Table

George Kelly Martin Buying and Selling Activity at TriSalus Life Sciences

This chart shows George Kelly Martin's buying and selling at TriSalus Life Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

TriSalus Life Sciences Company Overview

TriSalus Life Sciences logo
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
Read More

Today's Range

Now: $4.13
Low: $3.95
High: $4.16

50 Day Range

MA: $3.87
Low: $2.52
High: $4.65

2 Week Range

Now: $4.13
Low: $2.20
High: $7.95

Volume

102,456 shs

Average Volume

294,971 shs

Market Capitalization

$253.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49